cohort·critical care, infectious disease, pulmonology, epidemiology, observational study·PMC10616026
Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza
Annals of Intensive Care · 15 authors, 15 centres
AI SUMMARY
FIDELITY 100%
POPULATIONCritically ill ICU patients treated with invasive mechanical ventilation for at least 48 hours for either COVID-19 or influenza.
INTERVENTIONNot applicable (observational study).
COMPARISONCOVID-19 patients vs. influenza patients.
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
VAP was associated with an increased risk of day-60 mortality in COVID-19 patients, but not in influenza patients.
Full summary
645 CHARS
This retrospective cohort study analyzed 585 patients (503 with COVID-19, 82 with influenza) across 11 French ICUs who received invasive mechanical ventilation for at least 48 hours between January 2008 and June 2021. The primary outcomes were the incidence, microbiology, and association of VAP with day-60 mortality. Gram-negative bacilli were the most common microorganisms in both groups. In the overall cohort, VAP was associated with an increased risk of day-60 mortality (aHR=1.77 [1.36; 2.30]). This association was significant for COVID-19 patients (aHR=1.75 [1.32; 2.33]) but not for influenza patients (aHR=1.75 [0.48; 6.33], p=0.35).
PICO
PPOPULATION
Critically ill ICU patients treated with invasive mechanical ventilation for at least 48 hours for either COVID-19 or influenza.
IINTERVENTION
Not applicable (observational study).
OOUTCOME
Day-60 mortality related to VAP, VAP incidence, and microbiological documentation of VAP.
